Literature DB >> 22731821

A functional insertion/deletion polymorphism in the proximal promoter of CD3G is associated with susceptibility for hepatocellular carcinoma in Chinese population.

Lingling Jiang1, Jingya Xu, Jianqiang Ni, Xueren Gao, Zhansheng Zhu, Dong Dong, Xiaoshu Wang, Chunhua Shi, Xiaoyang Tao, Wanli Dong, Yuzhen Gao.   

Abstract

Hepatocellular carcinoma (HCC) represents the most common primary malignancy of the liver with a worldwide increasing incidence. Although the risk factors for HCC are well characterized, the molecular mechanisms responsible for malignant transformation of hepatocytes are not well understood. In this study, a case-control study including 291 HCC patients and 294 healthy controls was conducted to investigate the association between HCC susceptibility and with a 4-bp insertion/deletion polymorphism (rs66465034) in the proximal promoter of CD3G. Logistic regression analysis showed that the heterozygote and the homozygote 4-bp ins/ins confer a significantly increased risk of HCC after controlling for other covariates (adjusted odds ratio [OR]=1.51, 95% confidence interval [C.I.] 1.01-2.27, p=0.040; OR=1.71, 95% C.I. 1.07-2.89, p=0.025, respectively). Carriage of the 4-bp insertion allele was associated with a greatly increased risk of developing the disease (OR=1.30, 95% C.I. 1.02-1.64, p=0.027). Moreover, hepatitis B virus (HBV) stratification analysis showed that the differences between cases and controls were more obvious in HBV-positive than in the HBV-negative population, suggesting a possible role of this polymorphism in the immune regulation during HBV infection. Further, luciferase-based transient transfection assays revealed that rs66465034 can affect promoter activity of CD3G, indicating its possible functional significance. Our data suggested that common genetic polymorphisms in CD3G may influence HCC risk in Chinese population. Considering the relative small sample size, replication in other populations with larger sample size and further functional analysis are required for fully understanding the roles of CD3G polymorphisms in predisposition for HCC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22731821      PMCID: PMC3429282          DOI: 10.1089/dna.2012.1706

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  27 in total

1.  Cytotoxic T cell responses to human telomerase reverse transcriptase in patients with hepatocellular carcinoma.

Authors:  Eishiro Mizukoshi; Yasunari Nakamoto; Yohei Marukawa; Kuniaki Arai; Tatsuya Yamashita; Hirokazu Tsuji; Kiyotaka Kuzushima; Masafumi Takiguchi; Shuichi Kaneko
Journal:  Hepatology       Date:  2006-06       Impact factor: 17.425

2.  Chelex 100 as a medium for simple extraction of DNA for PCR-based typing from forensic material.

Authors:  P S Walsh; D A Metzger; R Higuchi
Journal:  Biotechniques       Date:  1991-04       Impact factor: 1.993

3.  T cell receptor zeta allows stable expression of receptors containing the CD3gamma leucine-based receptor-sorting motif.

Authors:  J Dietrich; C Geisler
Journal:  J Biol Chem       Date:  1998-10-09       Impact factor: 5.157

Review 4.  Complex complexes: signaling at the TCR.

Authors:  R L Wange; L E Samelson
Journal:  Immunity       Date:  1996-09       Impact factor: 31.745

Review 5.  Pathogenesis of hepatocellular carcinoma.

Authors:  Darius Moradpour; Hubert E Blum
Journal:  Eur J Gastroenterol Hepatol       Date:  2005-05       Impact factor: 2.566

6.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

Authors:  Qiang Gao; Shuang-Jian Qiu; Jia Fan; Jian Zhou; Xiao-Ying Wang; Yong-Sheng Xiao; Yang Xu; Yi-Wei Li; Zhao-You Tang
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

Review 7.  Organization of proximal signal initiation at the TCR:CD3 complex.

Authors:  Clifford S Guy; Dario A A Vignali
Journal:  Immunol Rev       Date:  2009-11       Impact factor: 12.988

8.  T lymphocyte development in the absence of CD3 epsilon or CD3 gamma delta epsilon zeta.

Authors:  B Wang; N Wang; C E Whitehurst; J She; J Chen; C Terhorst
Journal:  J Immunol       Date:  1999-01-01       Impact factor: 5.422

9.  Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.

Authors:  Mariana Capurro; Ian R Wanless; Morris Sherman; Gerrit Deboer; Wen Shi; Eiji Miyoshi; Jorge Filmus
Journal:  Gastroenterology       Date:  2003-07       Impact factor: 22.682

10.  CD3 gamma contains a phosphoserine-dependent di-leucine motif involved in down-regulation of the T cell receptor.

Authors:  J Dietrich; X Hou; A M Wegener; C Geisler
Journal:  EMBO J       Date:  1994-05-01       Impact factor: 11.598

View more
  2 in total

1.  Immunological analysis and differential genes screening of venous thromboembolism.

Authors:  Li-Na Gao; Qiang Li; Jian-Qin Xie; Wan-Xia Yang; Chong-Ge You
Journal:  Hereditas       Date:  2021-01-02       Impact factor: 3.271

2.  CD3D: a prognostic biomarker associated with immune infiltration and immunotherapeutic response in head and neck squamous cell carcinoma.

Authors:  Zhengyu Wei; Yiming Shen; Chongchang Zhou; Yujie Cao; Hongxia Deng; Zhisen Shen
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.